Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Illinois at Chicago
Memorial Sloan Kettering Cancer Center
University of Kansas Medical Center
Exelixis
SCRI Development Innovations, LLC
University of Pittsburgh
Massachusetts General Hospital
National Cancer Institute (NCI)
Fondazione Ricerca Traslazionale